Last reviewed · How we verify
Recurrent or advanced endometrial cancer
Approved treatments
- JEMPERLI · GLAXOSMITHKLINE
Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response. - Jemperli · GSK
Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Recurrent or advanced endometrial cancer patent landscape — cliff calendar, originator estates, attackable patents
- Recurrent or advanced endometrial cancer treatment landscape brief
- Recurrent or advanced endometrial cancer treatment updates RSS
Frequently asked questions about Recurrent or advanced endometrial cancer
What drugs treat Recurrent or advanced endometrial cancer?
Tracked treatments include JEMPERLI, Jemperli.
What is the treatment for Recurrent or advanced endometrial cancer?
Standard treatment for Recurrent or advanced endometrial cancer includes JEMPERLI, Jemperli. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Recurrent or advanced endometrial cancer patent cliff · Recurrent or advanced endometrial cancer CI report
- Treatment: JEMPERLI · GLAXOSMITHKLINE
- Treatment: Jemperli · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing